Covishield single-dose efficacy drops after 16 weeks in those above 60 years of age: Sri Lankan research

The efficacy of the single dose of Oxford-AstraZeneca COVID-19 vaccine Covishield dropped at 16 weeks for those above the age of 60, while 93 per cent of the younger population showed very good responses during the same duration, university research in Colombo has shown. The vaccine is produced by the University of Oxford and British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.

from IndiaTV India: Google News Feed https://ift.tt/2V7zLhA
via